Microbix specializes in developing proprietary biological technologies which have led to the development of a pipeline of products in three areas; Biotherapeutics, vaccines and non-therapeutic biologics.

We have a high value pipeline with three, near term opportunities, each of which could generate revenues over $100M per year.

Microbix' Core Base Virology Business was started in 1988 and today supplies infectious disease antigens to the diagnostic industry globally.  This business unit has generated substantial revenues, of which some have funded continuing operations and the bulk of which have been invested into the high value pipeline.